NCT02575365终止4 期
Effect of Fingolimod on Neurodegeneration, Brain Atrophy and Cognitive Impairment in Relapsing Remitting Multiple Sclerosis Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Change From Baseline in The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) Battery Test at 12 Months
研究概览
简要总结
This was a 24-month, open-label, multicenter study with a single treatment arm design.
Primary objective of this study was:
-To investigate the effects of Fingolimod on cognitive performance in highly active relapsing remitting multiple sclerosis patients
Secondary objectives of this study were:
- To investigate the correlation between the effect of fingolimod on cognitive performances and MRI data.
- To evaluate the effect of fingolimod on biomarkers (24 hydroxy cholesterol, osteopontin and matrix metalloproteinases) related to neurodegeneration
- To investigate the effect of fingolimod on brain gray matter atrophy and thalamic atrophy.
Polulation The hope was to recruit a minimum of 80 relapsing remitting MS (RRMS) patients according to the McDonald criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Diagnosed with RRMS as described in 2010 McDonald criteria (36)
- •Provided written informed consent prior to any intervention
- •Unresponsive to treatment with a beta interferon or glatiramer acetate for a minimum of one year at and at adequate dose and with high disease activity .
- •(Unresponsive patients: patients with no changes in relapses, increased relapses, severer relapses with one-year treatment or those who had had at least one relapse during the past one year under previous treatments and one or multiple contrast enhancing lesions in cranial MRI or increased T2 lesions in successive MRIs)
- •EDSS score below 5.5 at screening
排除标准
- •Patients with primary or secondary progressive or progressive relapsing MS.
- •Patients with known contraindications for fingolimod treatment.
- •Other coexistent autoimmune diseases including Hashimoto thyroiditis, systemic lupus erythematosus, rheumatoid anthiritis, psoriasis etc.
- •Patients with any of the following cardiovascular conditions:
- •Resting heart rate < 45 bpm/min
- •Cardiac failure at any time during the first study visit (Class III as per NYHA classification) or significant heart disease as judged by the physician
- •Myocardial infarction during the last 6 months
- •History of Mobitz Type II grade 2 AV block
- •Past or current grade 3 AV block
- •Confirmed history of sick sinus syndrome or sino-atrial heart block
- •arrhythmia requiring current treatment with Class Ia drugs (ajmaline, disopyramid, procainamide, quinidine)
- •hypertension uncontrolled with medication
- •History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- •Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, detected by urinalysis and confirmed by a positive hCG laboratory test.
- •Negative for varicella-zoster virus IgG antibodies at screening. Patients who have negative results for varicella-zoster virus IgG antibodies can be included in the study after vaccination for varicella-zoster virus.
- •Active systemic bacterial, viral or fungal infections, or diagnosis of AIDS, Hepatitis B, Hepatitis C infection defined as a positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests, respectively
- •History of previous fingolimod therapy
- •Patient who received any of the treatments below:
- •Corticosteroids or adrenocorticotropic hormone (ACTH) during the last 1 month
- •Immunosuppressive medications such as azathioprine or methotrexate etc.
- •Immunoglobulin treatment during the last 3 months
- •Cladribine, cyclophosphamide, mitoxantrone, natalizumab at any time
研究组 & 干预措施
Fingolimod arm
Experimental
0.5 mg p.o fingolimod daily
干预措施: 0,5 mg Fingolimod (Drug)
结局指标
主要结局
Change From Baseline in The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) Battery Test at 12 Months
时间窗: baseline , month 12.
The Brief International Cognitive Assessment for MS ( BICAMS Battery ) includes 3 cognitive tests, 1-Symbol Digit Modalities Test (SDMT, 2-the second edition of the California Verbal Learning Test (CVLT2) and 3-the revised Brief Visuospatial Memory Test (BVMTR).
Change From Baseline in The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) Battery Test at 24 Months
时间窗: baseline and month 24
The Brief International Cognitive Assessment for MS (BICAMS Battery) includes 3 cognitive tests, 1-Symbol Digit Modalities Test (SDMT, 2-the second edition of the California Verbal Learning Test (CVLT2) and 3-the revised Brief Visuospatial Memory Test (BVMTR).
次要结局
- Change From Baseline in PASAT Test(baseline ,months 6, month 12 and month 24)
- Change From Baseline in Serum Levels of 24S-hydroxycholesterol (24OHC) , Osteopontin and Matrix Metalloproteinases (and Also MMPI's)(baseline, month 6, month , month 12 and month 24)
- the Correlation Between Effect of Fingolimod on Cognitive Performances and Brain Atrophy (Gray Matter Atrophy and Thalamic Atrophy) by Comparing Baseline and Month 24.(baseline, month 24)
- Change From Baseline in Stroop Test(baseline, month 6, month 12 and month 24)
- Change From Baseline in Brain Gray Matter Atrophy and Thalamic Atrophy(baseline, month 6, month 12, month 18 and month 24)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
The efficacy of fingolimod in enhancing recovery after traumatic spinal cord injuryspinal cord injury.Injury, poisoning and certain other consequences of external causesT09.3IRCT20240701062291N1Mashhad University of Medical Sciences36
已完成
3 期
Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.Chronic Inflammatory Demyelinating PolyradiculoneuropathyNCT01625182Novartis Pharmaceuticals106
已完成
3 期
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisRelapsing-remitting Multiple SclerosisNCT00289978Novartis1,272
已完成
不适用
Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer AcetateMultiple SclerosisNCT02307877University of Colorado, Denver157
已完成
早期 1 期
Fingolimod as a Treatment of Cerebral Edema After Intracerebral HemorrhageIntracerebral HemorrhageStroke HemorrhagicIntracerebral Hemorrhage, HypertensiveIntracerebral Hemorrhage IntraparenchymalCerebral EdemaNCT04088630Wake Forest University Health Sciences28